annual list top potenti surpris new year includ event
underappreci invest commun least chanc occur
would associ signific stock price ramif
hope find thought stimul and/or entertain happi holiday -the cowen
effort stimul discuss aid out-of-the-box think scan
large- mid- small-cap coverag univers potenti surpris order qualifi
list surpris must constitut event less like well
discuss anticip market materi associ signific stock
price implic cowen biotech conjur ten event fit
definit rank order event like occur least like
occur necessarili advoc invest strategi surpris
rather hope open debat possibl interest potenti
util investor
icpt oca book nash sale
pleas see page report import disclosur
whether biotechnolog industri favor come year
featur number compani specif event make break
perform individu stock investor easili anticip mani binari
event exampl phase data argx efgartigimod immu
sacituzumab host regulatori action includ biib aducanumab bmrn
valrox gild/glpg filgotinib immu sacituzumab hope ph data
ptct/roch risdiplam tcda veverim inde mani investor alreadi
form opinion outcom mileston
howev biotechnolog natur unpredict new year like also
featur true surpris left field look back upon one
abl anticip take-out celg last year list re-valu smid
io stock last year list emerg advm aducanumab
success interim analysi last year list failur sage depress
studi last year list acquisit bold mdco return
would signific
effort stimul discuss aid out-of-the-box think
construct list top potenti surpris report follow
format top potenti surpris list publish past year order
qualifi list surpris must constitut event less like
well discuss anticip market materi associ signific
stock price implic cowen biotech conjur ten event
fit definit rank order event like occur
least like occur necessarili advoc invest strategi
surpris rather hope open debat possibl
interest potenti util investor
consensu view europ declin issu soliri patent
challeng patent must fatal flaw fact
second famili patent issu soliri -- must clear case doubl
patent expect pto invalid alxn patent would permit
 launch biosimilar pnh soon pivot trial complet
fda approv therefor face biosimilar competit soliri
eu erod price captur share alexion
surpris possibl file inter part review alexion
patent number key claim
patent claim patent specif amino acid
sequenc heavi light chain eculizumab claim stand
prevent launch biosimilar patent expir
petit rational behind pto decis institut ipr
make clear entir sequenc eculizumab never explicitli put
public domain prior file patent sequenc disclos
alexion initi eculizumab patent disclos
present public soliriss clinic data
argument person skill art could anticip amino acid
sequenc eculizumab part sequenc disclos patent
applic tpo-mimet us combin part
sequenc disclos patent
howev anticip requir prior art refer show claim
invent arrang combin way recit claim net moneyin
 inc neither patent applic tpo-mimet us
patent show full sequenc eculizumab amino acid
correct place construct eculizumab two would requir incorpor
heavi chain variabl domain patent antibodi scaffold us
tpo-mimet remov would appear meet
legal bar anticip given requir similar arrang
combin prior art suggest legal preced
therefor would seem quit possibl patent withstand amgen
challeng protect soliri biosimilar competit expiri
time event pto expect rule amgen ipr challeng
alexion patent august
stock impact surpris come true success defend soliriss ip
amgn challeng soliri would face biosimilar competit
expir patent
dcf analysi suggest current stock price assum sale alxn
franchis intern exclud japan declin begin
howev investor gain confid franchis sustain
alxn stock would worth increment even assum steep
declin sale impli stock price would appreci
defeat amgn ipr challeng
consensu view physician treat hemophilia conserv group
slow adopt new therapi good treatment avail today
long act factor viii hemlibra patient physician unwil
assum risk gene therapi patient probabl abl get gene
therapi life want make sure safeti efficaci
longev gene therapi well understood like via year commerci
experi opt moreov profil valrox good ideal
like hinder adopt interim phase data patient
achiev normal factor viii level iu/dl mean fviii level iu/dl
patient treat achiev fviii level even iu/dl impli
failur rate nearli biomarin analysi phase ii data impli
approxim year durat clinic meaning effect suggest
drug holiday function cure number gene therapi
hemophilia enter clinic trial wouldnt patient wait year see
one better profil hard see adopt valrox wont
surpris possibl expect valrox initi uptak low bloomberg
consensu call median mean valrox revenu
assum price per patient median estim assum patient
therapi mean estim anticip approv biomarin
remain track file fda approv valrox assum month
prioriti review valrox approv launch end
therefor consensu impli patient per month nation receiv
valrox
expect low much room upsid fact recent physician
check suggest proport hemophilia patient cue
valrox launch patient sever hemophiliac high rate
spontan bleed think gene therapi holi grail adopt even
durat expect eight ten year find prospect nearli
decad without factor replac spontan bleed entic moreov
physician report patient worri variabl
factor level produc care mostli bleed risk
recent data biomarin quit encourag reduct
mean annual bleed rate episod per year phase bleed
elimin patient includ lower factor viii
express level use one-stag factor viii assay patient non-
hemophil mild moder follow treatment valrox
patient remain sever reduct mean factor viii usag
week compar baselin vs infusions/year physician suggest
profil attract reason proport patient
wide rang estim number earli adopt among
hemophilia popul physician suggest could repres
sever hemophilia patient patient sever hemophilia repres
hemophilia patient fact one physician report patient offer spot
gene therapi trial want enrol notabl given even less
known valrox time impli patient may nearli interest
specif data investor assum
approxim individu hemophilia
classifi sever everi penetr hemophilia market
repres individu price per patient penetr
market would drive revenu
therefor would take mani earli adopt drive valrox revenu order
magnitud current consensu
expect time event
stock impact surpris come true estim today approxim
bmrn stock valrox dcf analysi suggest valrox would
worth approx achiev revenu grow
instead achiev grow
would worth approxim per share
though long-term trajectori valrox obvious determin first
quarter market suspect investor much will give
credit valrox multi- product earli launch handili
therefor valrox rapidli adopt consensu revenu estim
meaning exceed bmrn stock would like least could
much
consensu view polit rhetor around drug price like increas
presidenti elect approach moreov democrat
republican call drug price legisl quit possibl
enact elect matter parti win
unquestion bad biotech pharmaceut compani alik pharma
compani afraid transact understand rule law
chang biotech industri access capit constrain like pressur
valuat get readi tough year biotech stock
surpris possibl agre consensu polit rhetor
around drug price like increas elect year hous recent
pass drug price bill focus medicar price negoti though specif
bill unlik pass senat would veto trump administr
case clear signific focu control drug price
polit parti addit far year state across countri pass
drug price transpar bill bill differ wide requir
manufactur submit cost addit manufactur sale
market cost specif drug
environ pharma/biotech compani put forth best effort
justifi price exist drug well new futur drug launch believ
much argument reli cost drug develop
commonli cite industri ceo congression hear februari
 cost associ drug develop therefor could take increas
import negoti price medicar justifi price light current
polit scrutini could perhap even incorpor legisl propos
contrari consensu realist chanc could spur
problem industri face use cost account rule
mandat expens captur amount spent valu creat
differ two number quit dramat account
perspect actual valu becom visibl drug
licensed/acquir pharma compani pay premium biotech often record
multi- charg ipr small biotech compani launch first drug
may show much smaller cost larg pharma acquir drug
therefor view acquir could potenti negotiate/justifi higher price
drug develop cite data support point exampl
pharmasset spent total accumul deficit
acquir gilead upon launch sovaldi
price point gilead found defens justifi sovaldi price
substanti part gilead argument base spent pharmasset
would much difficult argument make gilead simpli creat similar
valu spend budget similar outcom seem quit
possibl polit push increas drug price transpar may enabl larg
pharma/biotech acquir negoti higher price new drug origin
innov potenti fuel late stage pre-commerci asset
spark
cowen compani
time event throughout
stock impact surpris come true recent acquisit premium paid
development biotech approach sometim exceed
stock acquir pipelin see substanti appreci
gener notic consist wave consolid would
expect nbi set all-tim close high nbi still peak
reach would anticip index would appreci least
much
companyacquirermain assetyearacquisit price multipl dkite deal announc feb closedacquisit price spend main asset mm cowen
consensu view larg cap biotech humbug larg cap middling-to-poor
fundament lacklust prospect top-lin growth mani face
competit threat gener biosimilar innov new therapi
pipelin rel poor certainli prolif enough drive re-acceler
revenu earn dividend yield either meager non-
exist though valuat cheap histor standard compani
nearli excit innov moreov presidenti
elect approach rhetor prescript drug price increas
wont improv either sentiment multipl thank thank look
surpris possibl earli sentiment larg cap biotech also
poor number larger compani trade high singl
low doubl digit multipl investor similarli pessimist prospect
group
howev launch success product begin re-energ
sector launch gilead hcv franchis biib tecfidera regn eylea
beat expect increas aggreg revenu growth biotech re-
invigor interest generalist investor flock biotech increas valuat
despit malais envelop investor sentiment larg cap today
potenti major drug launch vertex trikafta fda approv
octob virtu breakthrough-qu efficaci benign safeti
expect rapidli penetr elig cystic fibrosi popul recent
therapeut confer survey physician anticip least
 het min patient popul would trikafta month fda approv
think trikafta potenti handili outpac street consensu
ultim drive nearli cf franchis revenu
aducanumab also potenti blockbust prospect
fda approv emerg engag prime dataset controversi
question market opportun await make onto market
current peopl alzheim even modest
penetr market would yield multi- bb drug exampl estim
mild ad patient repres approxim total ad popul
peopl impli aducanumab label market would similar
size rheumatoid arthriti assum similar annual per patient price
aducanumab would address market mild alzheim without allow
use sever ad popul territori outsid
two launch alon would seem potenti re-invigor interest
growth investor one two addit product surpris libtayo
filgotinib larg cap could undergo re-rat similar
expect time event
stock impact surpris come true enter four biotech larg cap
market capit celg trade
averag price earn multipl six larg cap biotech market
capit today
strikingli similar situat averag trade price earn multipl
therefor think re-valu larg cap took place
could instruct potenti impact today larg cap
hand success product launch re-invigor interest
virtu product cycl end head averag
multipl four larg cap expand multipl expans
compound increas project earn cours four
larg cap appreci averag
therefor would seem possibl launch success
blockbust larg cap could increas averag pe multipl
combin upsid earn estim could expect result stock
appreci order
consensu view blockbust franchis checkpoint inhibitor
drug becom backbon immuno-oncology-bas treatment wide
array cancer transform treatment landscap still-substanti
shortcom term respons rate durabl creat still-signific unmet
need pursuit novel combin agent regimen address
opportun arguabl receiv signific level attent invest
across biopharmaceut industri particularli intrigu approach enhanc
efficaci therapi involv use oral administ drug
deriv gut bacteria microbiom either singl specif identifi strain
curat consortia bacteri speci consensu view approach
interest highli skeptic posit preclin data mice exampl provid
intrigu insight howev given complex interact gut
bacteria human immun system path toward proof seem varieg
complic unfold twist conform human gut
investor skeptic well reflect microbiom stock includ three publicli
trade biotech compani activ engag first-in-human clinic trial bacteri
drug oncolog evelo bioscienc chri shibutani ytd decemb
shibutani ytd respect effort target possibl indic oncolog
sole basi under-perform versu exampl btk
ytd believ almost level posit result upcom
human clinic data would definit surpris turn head un-scrunch
nose regard potenti bacteri drug cancer well infecti
immune-medi indic pursu
surpris possibl describ previous compel preclin
clinic data shown respons immunotherapi lack respons appear
associ bacteria gut evelo pharma evalu
potenti singl strain bacteria enhanc anti-tumor activ patient treat
keytruda merck sere investig potenti
biolog deriv consortium bacteria improv anti-tumor activ patient
treat opdivo bristol earli novemb evelo provid
initi insight on-going phase trial keytruda microsatellite-
stabl colorect cancer mss triple-neg breast cancer tnbc
relaps tumor compani disclos mss cohort fulli enrol
sever patient experienc extend stabl diseas moreov
tumor biopsi monotherapi lead-in period show chang
immun cell infiltr disclosur evelo pharma describ
preliminari observ phase trial keytruda patient
renal cell carcinoma rcc melanoma non-smal cell lung cancer nsclc
bladder cancer develop resist therapi among six
patient two partial respons remain studi data cutoff
addit patient stabl diseas one patient consent assess tumor
biomark increas level tumor-infiltr lymphocyt observ
follow treatment combin keytruda well toler
therefor earli result evelo pharma provid reason
encourag necessarili overwhelm single-strain approach
regard consortium-bas approach believ sere current lead way
compani yet provid data on-going clinic trial though preclin
evid support consortia-bas approach continu accumul three
promin academ lab laurenc zitvogel lab gustav roussi tom gajewski lab
univers chicago jennif wargo lab md anderson
publish data highli regard peer-review journal highlight observ
differ term microbiom profil patient respond
respond immun checkpoint inhibitor therapi intrigu datapoint
includ observ human fecal sampl respond non-
respond patient transfer mous tumor model respons checkpoint
inhibitor model mirror respons seen human donor
collabor md anderson parker institut cancer immunotherapi
sere conduct random placebo-control phase trial
donor-deriv microbiom consortium therapi patient unresect
metastat melanoma initi treatment opdivo first patient
treat march estim enrol patient treat
opdivo treat placebo opdivo reflect bacteri
signatur patient robust respons therapi
expect time event look compani present result
evelo expect present result phase trial
keytruda mss tnbc tumor addit
phase investigator-sponsor trial keytruda patient
melanoma naiv relaps prior inhibitor treatment underway
univers chicago estim data could avail given
start howev evelo longer provid guidanc time present
data trial pharma also plan provid addit data phase
trial keytruda rcc melanoma nsclc bladder cancer
precis time disclos although see possibl given
similar time evelo main cancer trial final sere expect present initi result
phase trial opdivo unresect metastat melanoma
stock impact surpris come true strong convinc signal activ one
earli on-going trial bacteri drug combin therapi could
transform individu compani stock question also
peer microbiom space prosecut translat effort oncolog would
peg respons rate bogey requir captur investor attent least
percentage-point absolut improv standard care exampl anti-
relaps nsclc respons rate least durat least six
month would consid clinic meaning accord expert consult
see conceiv stock impact well exceed respons rate percentag
fli drawn toward crave would expect
distinct aroma success waft beyond immedi commit roster asset
mention trigger microbiom player consid plop
effort io combo space make stickier attent array larg
pharma compani quest novel opportun invest whether
partnership acquisit
consensu view cder director janet woodcock icon drug develop
surpris isnt drug name yet janelizumab janemirsin
look fda consult believ model stabil
fda shepherd highest-profil agenc divis safeti scandal
multipl congression inquiri top-driven pro-innov evolut
recent re-organ cder rank file never known fda without
major culture-carri presenc key agenc moral way
senior personnel save mayb avuncular bob templ
inside-the-beltway account janet go anywher want
agenc govern brass want continu institut
knowledg moral let face flat agenc perform ye fan
surpris possibl woodcock fda sinc berlin wall
still reagan presid ritu learn ride bike janet
fda long time let face one work feder govern
money enter powerbal
woodcock also may strongest bench success candid
ever includ two would like sustain pro-innov etho per
establish track record bench includ cber director peter mark cder
deputi director oper patrizia cavazzoni cder offic new drug director
time event tomorrow novemb woman prerog chang
mind
stock impact surpris come true woodcock resign would send anxiou rippl
entir drug develop landscap neg impact directli
indirectli develop stage public compani stock investor biggest fear would
agenc dysfunct caus declin moral collater personnel chang
investor would also afraid potenti shift agenc pro-innov stanc
think impact would highli mitig woodcock appoint successor
see peter mark likeliest successor one would least
neg impact biotech landscap believ strongest
relev experi credenti highest public profil well-known well-lik
record strong advoc innov zolgensma review
think appoint peter stein would similarli reassur investor
appear janet deputi right hand signific number investor-
face appear event despit hold obviou heir-appar seat
recent serv interim princip deputi commission patrizia cavazzoni
shortest tenur fda well lowest public profil would
unknown quantiti investor repres largest uncertainti investor despit
join industri
surpris icpt oca book nash sale
consensu view success phase regener trial investor believ oca
approv nash launch around mid-year nda
accept pdufa date late march advis adcomm
schedul april suggest review could receiv delay
new late june action date would give ocaliva two quarter sale
investor expect initi launch quit modest three main reason
skeptic urgenc treat given oca efficaci data treatment effect
vs pbo primari endpoint percentag patient fibrosi
improv lower investor expect
uncertain patient identif diagnosi signific question remain
around patient identif gold standard diagnost methodolog
invas liver biopsi non-invas methodolog nash diagnosi
standard meaning high false-posit rate thought
terrif sensit modest diseas improv
insur coverag tell idea nash therapi
least expens plan purpos new diseas
consensu ocaliva nash sale consensu current
surpris possibl nacho nacho number increas preval
nash directli correl chang societ environ calor dens
option abound popey chicken sandwich anyon modern home technolog
neighborhood promot sedentari lifestyl two biggest
driver diseas mention preval nash estim
patient shout cowen favorit gogocurri kol indic
patient includ mayb nadeau known order triple-meat
pizza appropri pharmaceut treatment improv fibrosi current
consensu cowen estim suggest patient ocaliva
assum averag net annual price there probabl case nash
year driven fish stick alon fish stick gross that patient
target popul believ low-hang fruit larg dxd
advanc fibrosi patient hepatologist care repres penetr
rate low hang fruit end mmmmm pie needless say
signific reason potenti upsid consensu surpris
would suggest patient drug year end would still repres
percent diagnos advanc fibrosi patient popul urgent
requir treatment overal advanc fibrosi nash patient
time event strong momentum launch metric im could manifest
late
stock impact surpris come true smash consensu degre
would expect stock least doubl tripl bring compani back
close market cap number would impli motiv clinician patient
popul well easier insur access investor current anticip
would lift nash stock launch strong would re-ignit takeout
specul nash player ad extra boost valuat
improv access nash drug would also allow cowen team ventur
afield unhealthi lunch option chick-fil-a look
consensu view investor expect regeneron stay independ compani
one cinderella success stori sector compani
consid innov powerhous strong research capabl cutting-
edg antibodi bispecif engin manufactur platform strong
investor gener think larg cap biotech stock get acquir
especi given often meager cash flow volatil valuat unpredict
futur revenu lack clariti drug price reform larg cap take-out
far celgen acquisit unexpect anoth
deal seem unlik year come
regeneron particular acquir given eylea face tremend
competit headwind compani intertwin sanofi antibodi
collabor partner complic board structur wherein sanofi need
vote stake line broader board except compens equiti
financ specif matter
surpris possibl regeneron stock weak due concern
competit wamd novarti beovu show strong data head-to-head
hawk harrier trial vs regeneron eylea better dri beovu
launch dose octob could expand label
includ dose pend posit data head-to-head merlin trial
regeneron stock sensit eylea sale major valuat stem
franchis consensu estim predict beovu post
estim eylea post y/i mani investor
anticip eylea face strong headwind concern eylea market
eros continu pressur stock sidelin due
similar concern
contrast view sell-side consensu estim predict eylea post
y/i outlook show flattish trend share loss beovu
compens organ market growth share gain dme
valuat stock depress earlier recent post solid
upward momentum trade non-gaap ep due competit
headwind compound-annual-growth-rate revenu compound-annual-growth-rate ep valuat
even-keel stock could attract potenti acquir especi
eylea buck competit pressur maintain growth momentum
regeneron yield increas make
interest opportun especi cash flow eylea could protect
encroach competit nv beovu roch faricimab start
potenti biosimilar competitor also
test promis escal competit dynam anti-vegf therapi age-
occlus rvo diabet retinopathi dr
cowen compani thomson
given low interest rate environ scarc innov larg cap pharma
regeneron solid antibodi bispecif engin manufactur research
capabl compani could prize asset acquir regeneron deep
pipelin market-lead posit eylea could also highli attract
acquir final collabor agreement sanofi turn profit
bound becom lucr driven grow sale dupix
howev investor view acquisit long shot compani run
schleifer presid ceo georg yancopoulo presid cso
compani co-found staunch entrepreneur unlik
interest sell given credibl oper regeneron
experienc board mani long-standing member withstood
compani tribul year see manag board
interest sale
earli decemb sanofi/regeneron announc intent simplifi antibodi
collabor restructur royalty-bas agreement increas effici
streamlin oper like make compani even profit
potenti even attract suitor
decemb sanofi also said may sell part stake regeneron
lock-up period expir decemb essenc may path potenti
acquir buy stock sanofi move divest stake regeneron
could spark interest compani
howev attribut chanc notabl hurdl place
acquir stock size sanofi
addit manag like disinterest sell compani sever addit
element make acquir sizabl portion sanofi stake regeneron difficult
strateg entiti unless cours regeneron becom interest
facilit sale would ultim requir amend sanofi agreement
allow direct sale stake
one element agreement involv limit waiver provis allow
sanofi sell aggreg share regeneron stock fund certain
oblig sept thu far sanofi use share pay regeneron
reimburs expens incur part collabor sinc begin
share remain arrang like
sanofi use share way continu reimburs collabor
expens henc share unlik ever get sold third parti
limit much stock sold one entiti
underwrit charg place regn stock make best effort ensur
one entiti acquir ownership compani limit
circumv case lack demand share
interest parti ask sizabl chuck stock situat like
materi part normal stock sale process final regeneron also negoti
sanofi acquir stake sever year
therefor acquir sanofi stake whole part broader process
regeneron like requir agreement regeneron sanofi
consolid regeneron profit amount sanofi profit
henc sanofi profit would take sizabl hit divest
thu find regeneron may attract take-out target could gener
substanti cash flow acquir especi opex synergi realiz
attribut likelihood given tangibl hurdl
expect time event ye earli regeneron acquir would
like dec lock-up period expir altern done
conjunct agreement regeneron acquisit could
especi follow releas data libtayo nsclc
stock impact surpris come true done sensit analysi potenti
opex synergi acquir base dcf run scenario analysi show
potenti fair valu regeneron cash flow base reduct
opex base cost capit acquir
base dcf valuat given like cost capit acquir fair
valu could rang base reduct opex
cowen compani
consensu view consensu view like activ dealmak
activ focus earli stage research collabor
acquisit modest dermatolog and/or oncolog product singles/doubl
rather swing fenc
surpris possibl approxim revenu come
oral ruxolitinib jakafi jakavi royalti carri loe jakafi loe
yet critic overhang develop clear convinc approach soften
blow increas import set launch multipl new product
pemigatinib topic ruxolitinib etc next year howev mani investor view
opportun modest and/or subscal opportun furthermor investor
see littl tangibl proof incyt domin myeloprolif neoplasm
mpn market extend beyond jakafi
think signific overlap potenti prescrib base
blueprint avapritinib kit/pdgfr inhibitor asm ism gist pralsetinib ret
inhibitor nsclc exist plan commerci infrastructur
hematolog oncolog dermatolog furthermor blueprint product
expect gener signific revenu well beyond jakafi loe think
factor suffici provid strateg rational blueprint acquisit
beyond rational blueprint work inhibitor could also provid
viabl life cycl extens strategi jakafi competitor jak inhibitor momelotinib
disappoint primari efficaci endpoint spleen reduct mf also
demonstr intrigu anemia respons preclin data indic anemia
respons momelotinib driven off-target inhibit
altern name therefor ownership potent inhibitor could
provid opportun develop fix dose combin combin
jakafi market lead jak inhibit optim anti-anemia effect
inhibitor importantli blueprint partnership ipsen develop
inhibitor cover fop mo condit
total think clear strateg rational acquir blueprint
question whether parti agre price afford share
current trade fulli dilut ev recent biotech acquisit
premium therefor think acquisit blueprint
ev plausibl oper incom think could access
debt could combin cash balanc sheet fund
toward potenti acquisit remaind acquisit would need
fund share dilut current sharehold assum
close interest rate debt recogn
synergi rel stand-alone model
calcul transact would result chang ep
furthermor use npv analysi think transact would increas
sotp valuat share assum jakafi lcm modest
expect time event anytim
stock impact surpris come accord hypothet deal structur
share see increas sotp basi think move could
signific given reduct import jakafi eventu loe would also
repres upsid share
probabl thank constitut
consensu view presid trump controversi figur hold true
also biotech invest manag commun economi
steadi foot potenti trade deal china could provid boost
broad investor sentiment stock market hit all-tim high overal
market look beta risk trade underway biotech stock thrive
test two- five-year high despit on-going polit rhetor
attempt pass legisl would curtail continu escal drug price
attempt benchmark price us ex-u nation
consensu view presid trump continu push drug price reform either
via execut order eo earli forc implement controversi
price legisl support one congression
current consensu view whether presid trump get re-elect
sens biotech investor democrat candid biden
elizabeth warren view long shot prevail gener elect
key question whether trump get elect second term even
wonder whether trump tri stay addit term decid like
white hous perhap might even renov like
consid stay perman importantli role oval offic
second term possibl unless constitut amend coup detat
peg possibl
presid trump tenur offic mar ambival tone toward
biotech industri vocal critic drug price vitriol specif
discrep us ex-u price valuat biotech stock wax
wane sleepless concern legisl bring sky
fund innov kind disconcert one parti
thursday night even meet boss morn
fair say mani investor continu concern presid
rhetor implement view viabl risk part drug maker
particularli roch regeneron henc anoth trump term would sustain
overhang might come sharper focu start point
mani biotech investor predict current enthusiasm chase year-end
perform end
view given high likelihood senat remain republican
elect legisl unlik ever implement split congress
might good biotech
presid unpredict wonder whether gener
notion fals news start get carri biotech wherein investor view
neg result fals news therebi drive stock higher time ala
joke perhap broader market increasingli see polit nois
inconsist approach trade deal volatil broader stock
market remain albeit stock continu march upward trajectori would
also posit biotech
henc question whether perman trump presid even possibl
would consid dictatorship would good biotech frankli
happen point well bigger problem consid
surpris possibl investor concern execut order
eo viabl threat drug price believ long shot
discuss consult hill cowen washington
research group eo get challeng court propos use
demonstr author creat limit author never
defin drug maker would like good case polici
chang demo would also creat possibl drug would
avail part countri polit nightmar administr
what believ workabl written actual
reduc price drug instead cut amount doctor newli reconstitut
drug vendor would get paid drug littl incent distributor
take full risk plan either
reason plan outlin administr workabl
opinion howev would way modifi plan would like make
accept cap vendor make easier implement set
bid process similar medicar part would one way cours would
like reduc save estim would make plan real possibl
expect time event presid trump expect issu execut order
soon give us favor nation statu drug price medicar part
drug time might depend hous progress recent
approv hous senat help committe packag modest drug
price reform surpris bill pbm chang appear unlik get
vote year-end support think healthcar bill still get done earli next year
though viabl vehicl doubt year-end spend bill kill devic
cadillac tax well health insur fee hif
believ presid trump move issu eo earli broad drug
price agreement reach congress split congress legal
challeng like eo unlik becom viabl threat sector
ever
stock impact event come true believ long congress remain split
trump presid continu unpredict see littl chanc get
implement split congress would good biotech matter
perman trump presid split congress may also good biotech
joke asid envis implement legal challeng
biotech industri fail would send share outperform
regeneron market perform respect
assum differ price us ex-u
overal given current valuat factor implement see
move trump give effort congress sign drug bill
reason term reduc drug cost would final remov overhang
cowen compani
regeneron part exposur relat overhang
 exposur sale sale us total exposur sale sale us total cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
